skip to Main Content
Tilray® Strengthens Presence in Latin America with Acquisition of Alef Biotechnology

PRESS RELEASE

NANAIMO, British Columbia and SANTIAGO, Chile – Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research and production, today announced that it has completed an acquisition of its existing import and distribution partner Alef Biotechnology SpA (“Alef”). The acquisition will allow Tilray to import, produce and distribute Tilray branded medical cannabis products in Chile and to create a hub to distribute Tilray products throughout Latin America

Tilray purchased all the outstanding equity of Alef for approximately C$5,000,000 (Canadian dollars). The purchase was comprised of approximately C$250,000 in cash paid at closing, and C$4,750,000 in Tilray Class 2 common stock, subject to a standard working capital adjustment and Alef achieving certain business milestones within a twelve-month period after closing.

“Today’s announcement marks another milestone for Tilray as we expand our global footprint and solidify our presence in Latin America by officially welcoming Alef to the Tilray team,” said Brendan Kennedy, President and Chief Executive Officer of Tilray. “The Chilean government has been a pioneer legitimizing and regulating medical cannabis in Latin America, and we are thrilled to be investing in one of the region’s most exciting markets for biopharmaceutical development.”

Tilray previously announced a partnership with Alef in February 2017 to import and distribute Tilray products in Chile and Brazil. Alef is currently licensed by the Chilean government to commercially produce medical cannabis and is developing a state-of-the-art facility to domestically produce and process medical cannabis products. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician.

As a part of the acquisition, Tilray will retain current Alef employees Alan Nudman as Chief Executive Officer, and Ariel Nudman, as Chief Sales Officer. Alan and Ariel will oversee the strategic growth of Alef Biotechnology under the global leadership of Tilray.

“The agreement with Tilray is an incredibly exciting moment for Alef and the entire medical cannabis community in Latin America,” says Alan Nudman, Chief Executive Officer of Alef. “In partnership with Tilray, Alef was the first company to offer medical cannabis products through pharmacies anywhere in the Americas and we are looking forward to increasing access for patients throughout Latin America through this acquisition.”

For more information, please visit www.tilray.com.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Ahead of Emerald Cup Harvest Ball, cannabis growers raise alarm over taxes, regulations

About 30,000 cannabis enthusiasts are expected to trek through the Sonoma County Fairgrounds next weekend for the revamped Emerald Cup Harvest Ball, a celebration all about the plant that has been a social, regulatory and business fixture for decades in Northern California. Those pot lovers will learn about new, innovative weed strains, while some of…

State board decides against warning labels on cannabis products

The Vermont Cannabis Control Board has decided not to recommend specific warning labels on the health effects of cannabis products, and James Pepper, the board chair, explained to VTDigger how the board made the decision. The Vermont Medical Society urged the board and the Legislature this week to require warnings that cannabis and its main…

Groups From 56 Countries Ask UN To Ensure Secretive ‘Cannabis Initiative’ Is Open To Public Scrutiny

ONE year on from the formal recognition of the potential for cannabis as a medicine almost 200 global advocacy and civil society groups are backing for calls for greater transparency over emerging new cannabis guidelines. On December 2, last year the United Nations Commission on Narcotic Drugs (CND) rescheduled cannabis recognising its medical properties for…

San Francisco Suspends Cannabis Tax To Combat Illegal Marijuana Sales

SAN FRANCISCO (BCN) — San Francisco supervisors on Tuesday unanimously approved an ordinance to suspend the city’s Cannabis Business Tax through the end of next year, in an attempt to curb illegal marijuana sales. According to Supervisor Rafael Mandelman, the legislation’s author, suspending the city business tax through Dec. 31, 2022, would help support legal…

More Categories

Back To Top
×Close search
Search